Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Indicated for topical treatment of mild to moderate acne vulgaris
Subscribe to our email newsletter
Onset Therapeutics has launched BenzEFoam (benzoyl peroxide) 5.3% Emollient Foam, the first prescription foam formulation of benzoyl peroxide. BenzEFoam Emollient Foam is indicated for the topical treatment of mild to moderate acne vulgaris.
BenzEFoam Emollient Foam is formulated to address the needs of patients with body acne and to offer an ideal treatment option for them. BenzEFoam has demonstrated low rates of cutaneous irritation and dryness in clinical trials.
BenzEFoam Emollient Foam is proven to be very effective in reducing the acne-causing bacteria P acnes, on the back. In a clinical trial, BenzEFoam demonstrated a greater than 100-fold reduction in P acnes counts after two weeks of use.
Hilary Baldwin, vice chair and associate professor of department of dermatology at State University of New York (SUNY)-Brooklyn, said: “Benzoyl peroxide is a mainstay of acne treatment. Dermatologists have been waiting for a foam formulation of benzoyl peroxide. We believe patients prefer and are more compliant with applying foam formulations for skin conditions affecting broad body areas. BenzEFoam is a good treatment option for chest and back acne, as well as for acne in hairy areas.”
Doug Abel, general manager of Onset Therapeutics, said: “We are excited to bring BenzEFoam Emollient Foam as a new body acne treatment option to dermatologists and their patients. We believe this is a topical therapy which may improve outcomes in patients with acne appearing on the chest and back because it is effective, well tolerated, and easy to spread over these larger areas.”
Michael Heffernan, president of Onset Therapeutics, said: “The development of the first prescription benzoyl peroxide emollient foam is a major accomplishment for Onset Therapeutics. The clinical results combined with the feedback from dermatologists confirm our strong belief in the value of the Delevo Foam Technology and its applicability to many different active ingredients for the treatment of dermatologic conditions. The launch of BenzEFoam Emollient Foam, our second major product launch this year along with Hylatopic Emollient Foam, is a testament to our product development team and the extensive product pipeline that they have developed.”